New study aims to replace costly PET scans with MRI and blood tests for Alzheimer's patients
NCT ID NCT07456462
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study will test whether advanced MRI scans and blood tests can predict how well Alzheimer's patients respond to antibody drugs like lecanemab and donanemab. Researchers aim to create personalized models that show when amyloid plaques have been cleared from the brain, potentially replacing expensive PET scans. Fifty participants with early Alzheimer's will be followed for 18 months to see if these non-invasive methods can guide treatment decisions.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
monoclonal antibodies (lecanemab or donanemab)
What this could lead to
If successful, this could lead to a safer, cheaper way to monitor Alzheimer's treatment and decide when to stop medication, tailored to each patient.
What could go wrong
This is a small, early-stage study with only 50 participants, so results may not apply to everyone. The models are still being developed and may not accurately predict treatment response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MILD COGNITIVE IMPAIRMENT (MCI) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
San Raffaele Neurology Unit
Milan, Milano, 20132, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact